|
市場調査レポート
商品コード
1789244
眼炎症治療市場規模、シェア、成長分析、薬剤クラス別、剤形別、流通チャネル別、地域別 - 産業予測、2025年～2032年Ocular Inflammation Treatment Market Size, Share, and Growth Analysis, By Drug Class (Corticosteroids, Antibiotics), By Dosage Form (Eye drops, Tablets), By Distribution Channel, By Region - Industry Forecast 2025-2032 |
||||||
|
|||||||
| 眼炎症治療市場規模、シェア、成長分析、薬剤クラス別、剤形別、流通チャネル別、地域別 - 産業予測、2025年～2032年 |
|
出版日: 2025年08月08日
発行: SkyQuest
ページ情報: 英文 183 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
眼炎症治療の世界市場規模は2023年に4億2,870万米ドルと評価され、2024年の7億34万米ドルから2032年には9億9,950万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.1％で成長する見通しです。
世界の眼炎症治療市場は、革新的な生物製剤と標的治療薬によって大きな成長を遂げています。ぶどう膜炎や強膜炎などの疾患の有病率の上昇により、低侵襲で安全な治療オプションに対する需要が高まっています。徐放性システムや局所療法などのドラッグデリバリーの進歩により、治療法が拡大し、患者のアドヒアランスと治療成績が向上しています。さらに、早期診断の重要性に関する医療界の認識が高まったことで、より早く治療を求める患者が増えています。製薬会社や研究機関は、満たされていない臨床ニーズに対応し、視力低下のリスクを軽減するため、モノクローナル抗体や低分子阻害剤などの新薬に多額の投資を行っています。しかし、これらの新治療の長期的な安全性と有効性に関する継続的な議論とともに、特に低所得地域におけるアクセスや価格に関する課題が残っています。
目次
イントロダクション
- 調査の目的
- 調査範囲
- 定義
調査手法
- 情報調達
- 二次と一次データの方法
- 市場規模予測
- 市場の前提条件と制限
エグゼクティブサマリー
- 世界市場の見通し
- 供給と需要の動向分析
- セグメント別機会分析
市場力学と見通し
- 市場概要
- 市場規模
- 市場力学
- 促進要因と機会
- 抑制要因と課題
- ポーターの分析
主な市場の考察
- 重要成功要因
- 競合の程度
- 主な投資機会
- 市場エコシステム
- 市場の魅力指数（2024年）
- PESTEL分析
- マクロ経済指標
- バリューチェーン分析
- 価格分析
- ケーススタディ
- 技術分析
- 顧客購買行動分析
眼炎症治療市場規模：薬剤クラス別& CAGR（2025-2032）
- 市場概要
- コルチコステロイド
- 抗生物質
- モノクローナル抗体
- 抗真菌薬
- 毛様体麻痺薬
眼炎症治療市場規模：剤形別& CAGR（2025-2032）
- 市場概要
- 目薬
- 錠剤
- カプセル
眼炎症治療市場規模：流通チャネル別& CAGR（2025-2032）
- 市場概要
- 病院薬局
- 小売薬局
- オンライン薬局
眼炎症治療市場規模：地域別& CAGR（2025-2032）
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ
競合情報
- 上位5社の比較
- 主要企業の市場ポジショニング（2024年）
- 主な市場企業が採用した戦略
- 最近の市場動向
- 企業の市場シェア分析（2024年）
- 主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）
主要企業プロファイル
- AbbVie Inc.
- Alcon Laboratories Inc.
- Alimera Sciences, Inc.
- Amgen Inc.
- Bausch Health Companies Inc.
- Bayer AG
- EyePoint Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc（GSK）
- Johnson & Johnson Services Inc.
- Novartis AG
- Ocular Therapeutix, Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
結論と提言
Global Ocular Inflammation Treatment Market size was valued at USD 428.7 Million in 2023 and is poised to grow from USD 700.34 Million in 2024 to USD 999.5 Million by 2032, growing at a CAGR of 6.1% in the forecast period (2025-2032).
The global ocular inflammation treatment market is experiencing significant growth driven by innovative biologics and targeted therapies. The rising prevalence of conditions like uveitis and scleritis has heightened the demand for minimally invasive, safe treatment options. Advances in drug delivery, such as sustained-release systems and localized therapies, have expanded the therapeutic landscape, improving patient adherence and outcomes. Furthermore, increased awareness within the medical community regarding the importance of early diagnosis has led to more patients seeking care sooner. Pharmaceutical companies and research institutions are heavily investing in novel drugs, including monoclonal antibodies and small molecule inhibitors, to address unmet clinical needs and reduce the risk of vision loss. However, challenges persist, particularly concerning access and affordability, especially in lower-income regions, alongside ongoing discussions regarding the long-term safety and efficacy of these new treatments.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ocular Inflammation Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ocular Inflammation Treatment Market Segments Analysis
The global ocular inflammation treatment marketis segmented into drug class, dosage form, distribution channel, and region. By drug class, the market is classified into corticosteroids, antibiotics, monoclonal antibodies, antifungals, and cycloplegic agents. Depending on the dosage form, it is divided into eye drops, tablets, and capsules. According to distribution channel, the market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Driver of the Global Ocular Inflammation Treatment Market
A significant driver of the global ocular inflammation treatment market is the rising prevalence of eye disorders such as conjunctivitis, uveitis, and iritis, which are particularly common among the aging population, as older individuals are more susceptible to inflammation-related eye conditions. This trend is further fueled by heightened awareness regarding the importance of ocular health and the benefits of early diagnosis, prompting more patients to seek timely medical advice. Additionally, the increasing financial burden associated with managing these diseases is propelling the demand for effective treatment options, thereby fostering growth and innovation within the market.
Restraints in the Global Ocular Inflammation Treatment Market
A significant challenge facing the Global Ocular Inflammation Treatment market is the high cost associated with treating complex ocular inflammation. The expenses related to biologic agents and advanced delivery systems can create barriers to access, particularly in low- and middle-income regions. Moreover, in wealthier markets, complications related to reimbursement and the burden of out-of-pocket expenses can dissuade patients from pursuing the latest therapeutic options. These financial obstacles hinder widespread adoption of innovative treatments and may ultimately impact the overall growth of the market. Addressing these economic concerns is essential for enhancing accessibility to effective ocular inflammation therapies.
Market Trends of the Global Ocular Inflammation Treatment Market
The Global Ocular Inflammation Treatment market is experiencing notable developments driven by the rising adoption of biologic therapies and advancements in drug delivery systems. Biologic treatments, which target specific inflammatory pathways, are gaining traction due to their enhanced efficacy and reduced side effects compared to traditional options. Concurrently, innovations in drug delivery methods, such as sustained-release implants and localized therapies, are fostering better patient adherence and improved clinical outcomes. This momentum is supported by ongoing research, favorable regulations for emerging therapies, and a pressing need for effective, long-lasting solutions for chronic ocular inflammatory conditions, ultimately transforming patient care in this domain.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Technology Analysis
- Customer Buying Behavior Analysis
Global Ocular Inflammation Treatment Market Size by Drug Class & CAGR (2025-2032)
- Market Overview
- Corticosteroids
- Antibiotics
- Monoclonal Antibodies
- Antifungals
- Cycloplegic Agents
Global Ocular Inflammation Treatment Market Size by Dosage Form & CAGR (2025-2032)
- Market Overview
- Eye drops
- Tablets
- Capsules
Global Ocular Inflammation Treatment Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Ocular Inflammation Treatment Market Size & CAGR (2025-2032)
- North America (Drug Class, Dosage Form, Distribution Channel)
- US
- Canada
- Europe (Drug Class, Dosage Form, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Dosage Form, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Dosage Form, Distribution Channel)
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Dosage Form, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alcon Laboratories Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alimera Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- EyePoint Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (GSK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneron Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
